| Relative glomerular hyperfiltration in primary aldosteronism. | |
| | |
MedLine Citation:
|
PMID: 15800124 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Experimental and clinical data suggest that primary aldosteronism (PA) may be associated with cardiovascular hypertrophy and fibrosis, in part independent of the BP level. Whether PA may also result in specific deleterious effects on the kidneys was less studied. In 25 patients with tumoral PA, renal studies (urinary excretion of proteins, GFR, and effective renal plasma flow [ERPF], as clearances of technetium-labeled diethylene triaminopentaacetic acid and 131I-ortho iodohippurate, respectively) were performed both before and 6 mo after surgical cure. A control group consisting of patients with essential hypertension (EH) was studied before and after 6 mo of antihypertensive therapy. At baseline, PA and EH patients were similar with respect to demographic data, duration and level of hypertension, and GFR and ERPF. Urinary excretion of albumin and beta2 microglobulin were higher in PA than EH (88 +/- 26 versus 39 +/- 12 and 0.91 +/- 0.23 versus 0.26 +/- 0.19 mg/24 h, respectively; both P < 0.05). Adrenalectomy was followed by a decrease in arterial BP (by 28 +/- 3/13 +/- 2 mmHg), urinary excretion of albumin and beta2 microglobulin (by 48 +/- 19 and 0.53 +/- 0.21 mg/24 h, respectively), and GFR and ERPF (by 15 +/- 3 and 54 +/- 15 ml/min per 1.73 m(2), respectively). In EH, a similar decrease in pressure was associated with a decrease in albuminuria but no change in GFR or ERPF. In 17 of the 25 PA patients who received a 6-mo treatment of spironolactone, both GFR and ERPF decreased in parallel with BP, similar to what was observed after surgery. These data suggest that PA was associated with relative hyperfiltration, unmasked after suppression of aldosterone excess. |
| | |
Authors:
|
Jean Ribstein; Guilhem Du Cailar; Pierre Fesler; Albert Mimran |
Related Documents
:
|
7662224 - Spectral characteristics of heart rate and blood pressure variability in primary aldost... 2743584 - Central administration of aldosterone increases blood pressure in rats. 3326694 - Hemodynamic and neurohumoral factors in the response of hypertensives to hydrochlorothi... 14517164 - Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential h... 21096164 - Mechanical analysis of an oscillatory positive expiratory pressure device used in respi... 10543334 - Female bladder neck changes with position. |
Publication Detail:
|
Type: Journal Article Date: 2005-03-30 |
Journal Detail:
|
Title: Journal of the American Society of Nephrology : JASN Volume: 16 ISSN: 1046-6673 ISO Abbreviation: J. Am. Soc. Nephrol. Publication Date: 2005 May |
Date Detail:
|
Created Date: 2005-04-28 Completed Date: 2005-08-31 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9013836 Medline TA: J Am Soc Nephrol Country: United States |
Other Details:
|
Languages: eng Pagination: 1320-5 Citation Subset: IM |
Affiliation:
|
Department of Medicine, Hôpital Lapeyronie, 34295 Montpellier cedex 5, France. j-ribstein@chu-montpellier.fr |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adenoma
/
complications,
surgery Adrenal Cortex Neoplasms / complications, surgery Adult Aged Aldosterone Antagonists / therapeutic use Blood Pressure Female Glomerular Filtration Rate* Humans Hyperaldosteronism / drug therapy, etiology, physiopathology* Kidney Glomerulus / metabolism, physiopathology* Male Middle Aged Renal Circulation Renin-Angiotensin System / physiology Spironolactone / therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Aldosterone Antagonists; 52-01-7/Spironolactone |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: High lipoprotein(a) levels and small apolipoprotein(a) size prospectively predict cardiovascular eve...
Next Document: Vacuolar H+-ATPase d2 subunit: molecular characterization, developmental regulation, and localizatio...